Nosocomial outbreak of OXA-18-producing Pseudomonas aeruginosa in Tunisia.
Following systematic screening for ceftazidime-resistant (CAZ-R) Pseudomonas aeruginosa, 24 isolates producing extended-spectrum beta-lactamase (ESBL) were recovered during a 24-month period at the National Bone Marrow Transplant Centre of Tunisia. These isolates were from seven immunocompromised patients and from environmental swabs. ESBLs inhibited by clavulanic acid were detected by double-disk diffusion tests. Isoelectric focusing revealed that these isolates produced two to four beta-lactamases with pIs of 5.5, 6.1, 6.4, 7.6 or 8.2, and PCR detected the presence of bla(OXA-18), bla(SHV) and bla(TEM) genes in 24, 21 and two isolates, respectively. Pulsed-field gel electrophoresis defined two dominant genotypic groups: group A (16 isolates) and group B (four isolates). Sequencing of PCR products from representative isolates identified the bla(OXA-18) gene and revealed nucleotide sequences belonging to the bla(SHV-1) and bla(TEM-1) genes. Isolates producing OXA-18 belonged to genomic group A and were isolated from four immunocompromised patients in the haematology and graft units, and from two wash-basins in the graft unit. No immunocompromised patient harboured the clonal epidemic strain upon admission. This is the first report of the OXA-18-type ESBL in P. aeruginosa in Tunisia, and the first description of an outbreak caused by an OXA-18-producing strain of P. aeruginosa.
Kalai Blagui
S
S
Unité de Recherche, Laboratoire de Bactériologie Médicale, Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.
Achour
W
W
Abbassi
M S
MS
Bejaoui
M
M
Abdeladhim
A
A
Ben Hassen
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002442:Ceftazidime / Q000494:pharmacology; D003428:Cross Infection / Q000382:microbiology*; D004196:Disease Outbreaks; D006801:Humans; D016867:Immunocompromised Host; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000235:genetics*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics; D014416:Tunisia / Q000453:epidemiology; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002442:Ceftazidime; C108862:beta-lactamase OXA-18; D001618:beta-Lactamases